Corticotropin releasing factor 2 receptor agonists

Details Corticotropin releasing factor 2 receptor agonists Corticotropin releasing factor 2 receptor agonists

2007-03-20

2007-03-20

Russel, Jeffrey Edwin (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S021800, C530S324000

Reexamination Certificate

active

10315964

ABSTRACT:
Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.

REFERENCES:
patent: 5235036 (1993-08-01), Kornreich et al.
patent: 5663292 (1997-09-01), Rivier
patent: 5786203 (1998-07-01), Lovenberg et al.
patent: 5824771 (1998-10-01), Rivier
patent: 5844074 (1998-12-01), Rivier
patent: 5869450 (1999-02-01), Wei et al.
patent: 0 860 501 (1998-08-01), None
patent: WO 96/37223 (1996-11-01), None
patent: WO 97/00063 (1997-01-01), None
patent: WO 97/32898 (1997-09-01), None
patent: WO 02/12307 (2002-02-01), None
patent: WO 02/34934 (2002-05-01), None
T.M. Reyes, et al., “Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors”,PNAS, vol. 98, No. 5, pp. 2843-2848 (2001).
E.B De Souza, et al., “Corticotropin-Releasing Factor Receptors: Physiology, Pharmacology, Biochemistry and Role In Central Nervous System and Immune Disorders”,Psychoneuroendocrinology, Elsevier Science Ltd., USA, vol. 20, No. 8, pp. 789-819 (1995).
D.T. Chalmers, et al., “Corticotropin-releasing factor receptors: from molecular biology to drug design”,TiPS, Elsevier Science Ltd., USA, vol. 17, pp. 166-172, (1996).
H.A. Thomas, et al., “CRF and Related Peptides as Anti-Inflammatory Agonists”,Annals New York Academy of Sciences, pp. 219-228 (1993).
E.T. Wei, et al., “Peripheral anti-inflammatory actions of corticotropin-releasing factor”,Ciba Foundation Symposium 172, Wiley, Chichester , pp. 258-276, (1993).
J.R. McCarthy, et al., “Recent Advances with the CRF1Receptor: Design of Small Molecule Inhibitors, Receptor Subtypes and Clinical Indications”,Current Pharmaceutical Design, , Bentham Science Publishers B.V. vol. 5 pp. 289-315 (1999).
J.R. McCarthy, et al., “Chapter 2. Recent Progress in Corticotropin-Releasing Factor Receptor Agents”,Annual Reports in Medicinal Chemistry, Academic Press, vol. 34, pp. 11-20 (1999).
G.P. Chrousos, et al., “Corticotropin Releasing Factor: Basic Studies and Clinical Applications”,Prog. Neuro-Psychopharmacol.&Biol. Psychiat., Pergamon Press Ltd, Great Britain, vol. 9, pp. 349-359 (1985).
G.B. Cutler, Jr., M.D., “Corticotropin-Releasing Hormone (CRH): Clinical Studies and Use”,The Endocrinologist, Suppl. 1, Williams & Wilkins, vol. 7, No. 1, pp. 10S-16S (1997).
M.J. Owens, et al., “Physiology and Pharmacology of Corticotropin-releasing Factor”,Pharmacological Reviews, The American Society for Pharmacology and Experimental Therapeutics, USA. vol. 43, No. 4, pp. 425-473 (1991).
L. Arborelius, et al., “The role of corticotropin-releasing factor in depression and anxiety disorders”,Journal of Endocrinology, Society for Endocrinology, Great Britain, vol. 160, pp. 1-12 (1999).
D.N. Orth, “Corticotropin-Releasing Hormone in Humans”,Endocrine Reviews, The Endocrine Society, USA., vol. 13, No. 2, pp. 164-191 (1992).
E. Emeric-Sauval, “Corticotropin-Releasing Factor(CRF)—A Review”,Psychoneuroendocrinology, Pergamon Journals Ltd., Great Britain, vol. 11, No. 3, pp. 277-294 (1985).
J. Spiess, et al., “Molecular Properties of the CRF Receptor”,TEM, Elsevier Science Ltd., vol. 9, No. 4, pp. 140-145 (1998).
K.D. Dieterich, et al., “Corticotropin-releasing factor receptors: An overview”,Exp. Clin. Endocrinol. Diabetes, Johann Ambrosius Barth, vol. 105, pp. 65-82 (1997).
P.J. Gilligan, et al., “Corticotropin Releasing Factor (CRF) Receptor Modulators: Progress and Opportunities for New Therapeutic Agents”,Journal of Medicinal Chemistry, American Chemical Society, vol. 43, No. 9, pp. 1641-1660 (2000).
C.A. Maltin, et al., “Clenbuterol, a β-adrenoceptor agonist, increases relative muscle strength in orthopaedic patients”,Clinical Science, vol. 84, pp. 651-654 (1993).
J.F. Signorile, et al., “Increased Muscle Strength in Paralyzed Patients after Spinal Cord Injury: Effect of Beta-2 Adrenergic Agonist”,Arch Phys Med Rehabil, vol. 76. pp. 55-58 (1995).
L. Martineau, et al., “Salbutamol, a β2-adrenoceptor agonist, increases skeletal muscle strength in young men”,Clinical Science, vol. 83, pp. 615-621 (1992).
M.H. Perrin, et al., “Diverse roles of corticotropin releasing factor receptors and their ligands”,Amer. Zoologist, vol. 40, No. 6, pp. 1168-1169 (2000).
O. Valdenaire, et al., “A new functional isoform of the human CFR2 receptor for corticotropin releasing factor”,Biochimica et Biophysica Acta, vol. 1352, pp. 129-132 (1997).
M.R Palchaudhuri, et al., “Isolation and pharmacological characterization of two functional splice variants of corticotropin-releasing factor type 2 receptor from Tulpaia belangeri”,J. of Neuroendocrinology, vol. 11, pp. 419-428 (1999).
D.E. Grigoriadis, et al., “125I-Tyr0-Sauvagine: A novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor2areceptors”,Molecular Pharmacology, vol. 50, pp. 679-686 (1996).
N. Suman-Chauhan, et al., “Expression and characterisation of human and rat CRF2areceptors”,Eur. J. Pharmacol., vol. 379, pp. 219-227 (1999).
T. Kishimoto, et al., “A sauvagine/ corticotropin-releasing factor receptor expressed in heart and skeletal muscle”,Proc. Natl. Acad. Sci. USA, vol. 92, pp. 1108-1112 (1995).
T. Bale, et al., “Mice Deficient for Both Corticotropin-Releasing Factor Receptor 1 (CRFR1) and CRFR2 Have an Impaired Stress Response and Display Sexually Dichotomous Anxiety-Like Behavior”,The Journal of Neuroscience, vol. 22, No. 1, pp. 193-199 (2002).
M. Perrin, et at., “Corticotropin Releasing Factor Receptors and Their Ligand Family”,Annals New York Academy of Sciences, pp. 312-328, (not dated).
K. Lewis, et al., “Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor”,PNAS, vol. 98, No. 13, pp. 7570-7575, (2001).
S. Hsu, et al., “Human stresscopin and stesscopin—related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor”,Nature Medicine, vol. 7, No. 5, pp. 611 (2001).
H. Appell, et al., “Muscular Atrophy Following Immobilisation A Review”,Sports Medicine, vol. 10, No. 1, pp. 42-58 (1990).
G. Smith, et al., “Corticotropin Releasing Factor Receptor 1—Deficient Mice Display Decreased Anxiety, Impaired Stress Response, and Aberrant Neuroendocrine Development”,Neuron, vol. 20 pp. 1093-1102 (1998).
C. Rossant, et al., “Corticotropin-Releasing Factor Type 1 and Type 2a Receptors Regulate Phosphorylation of Calcium/Cyclic Adenosine 3',5'-Monophosphate Response Element-Binding Protein and Activation of p42/p44 Mitogen-Activated Protein Kinase”,Endocrinology, vol. 140, No. 4, pp. 1525-1536 (1999).
K. Heldwein, et al., “Corticotropin-Releasing Hormone Receptor Expression and Functional Coupling in Neonatal Cardiac Myocytes and AT-1 Cells*”,Endocrinology, vol. 137, No. 9, pp. 3631-3639 (1996).
Y. Kuryshev, et al., “Corticotropin-Releasing Hormone Stimulation of Ca2+Entry in Corticotropes Is Partially Dependent on Protein Kinase A*”,Endocrinology, vol. 136, No. 9, pp. 3925-3935 (1995).
T. Lovenberg, et al., “CRF2αand CRF2βreceptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues.”Endocrinology, vol. 136, No. 9, pp. 4139-4142 (1995).
M. Tisdale, et al., “Biology of Cachexia”,Journal of the National Cancer Institute, vol. 89, No. 23, pp. 1763-1773 (1997).
S. Coste, et al., “Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotr

Affiliated with

Also associated with

Rating

Corticotropin releasing factor 2 receptor agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Corticotropin releasing factor 2 receptor agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Corticotropin releasing factor 2 receptor agonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3735847